MDT-AP-0074
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 177.96
- os_event
- false
- age_years
- 3.29
- sex
- M
- new_clusters
- C4
- umap1_2d
- 3.006040868
- umap2_2d
- 4.824008148
- umap1_3d
- 1.533704116
- umap2_3d
- -1.655238738
- umap3_3d
- -3.98392435
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.390
- MTORC1_SIGNALING+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.260
- TGF_BETA_SIGNALING+0.240
- PI3K_AKT_MTOR_SIGNALING+0.210
- HEDGEHOG_SIGNALING+0.190
- MITOTIC_SPINDLE+0.190
- E2F_TARGETS+0.180
- UV_RESPONSE_DN+0.180
- G2M_CHECKPOINT+0.170
Top 10 suppressed
- KRAS_SIGNALING_DN-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- HYPOXIA-0.230
- INFLAMMATORY_RESPONSE-0.200
- PANCREAS_BETA_CELLS-0.190
- ESTROGEN_RESPONSE_LATE-0.180
- MYOGENESIS-0.180
- P53_PATHWAY-0.180
- APICAL_SURFACE-0.170
- ESTROGEN_RESPONSE_EARLY-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_7G42J2SK | EPN | Supratentorial EPN | 0.801 |
| 2 | SRR1797288 | — | cohortSC | 0.782 |
| 3 | SRR1797284 | — | cohortSC | 0.777 |
| 4 | SRR934721 | — | — | 0.763 |
| 5 | MDT-AP-3313 | Med | Medulloblastoma | 0.751 |
| 6 | SRR934928 | — | — | 0.749 |
| 7 | MDT-AP-3205 | Med | Medulloblastoma | 0.746 |
| 8 | MNG730 | — | — | 0.744 |
| 9 | ERR2598102 | fetal | fetal | 0.743 |
| 10 | SRR934914 | — | — | 0.743 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |